Singapore, 16 February 2022 – Researchers from the National Cancer Centre Singapore have found a potential new strategy to treat peritoneal carcinomatosis, a metastatic form of intra-abdominal cancer, where patients are presented with limited treatment options and poor overall survival. Published in
Cell Reports Medicine on 15 February 2022, the findings provide a way to identify more effective treatments for patients with metastatic intra-abdominal cancers by targeting what fuels cancer cells.
A widely accepted scientific hypothesis is that cancer (“seed”) spreads onto the organ surfaces (“soil”) through a series of complex interactions in the body. Most cancer treatments directly target the “seed” such as through the use of chemotherapy, which inhibits cancer cell division. In the last nine years, immunotherapy has become increasingly popular as a means of cancer treatment, altering the “soil” by enlisting the body’s immune system to target cancer cells.1 In this latest research from the Laboratory of Applied Human Genetics at NCCS, findings show it is possible to target “water” to create an arid environment thus making it inhospitable for tumour cell growth.
The team of researchers, led by NCCS clinician-scientist Assistant Professor Chin-Ann Johnny Ong, identified that ascites, excess fluid (“water”) present in the abdomen of patients with metastatic intra-abdominal cancers, can be directly targeted to remove the fuel that drives cancer growth. By interrogating the proteins in ascites, the team found that PAI-1 (plasminogen activator inhibitor 1) is a good marker of response to direct inhibition and could potentially curb cancer cell proliferation. Prior to the team’s discovery, PAI-1 was not known to be related to the growth of intra-abdominal cancers.
Using biological samples from 156 intra-abdominal cancer patients, Asst Prof Ong and team further identified a panel of three biomarkers that could predict patient outcomes as well as responsiveness to PAI-1 therapy. The findings were confirmed with models incorporating the tripartite combination of “seed”, “soil” and “water”.
“Our study not only highlights a novel treatment strategy for peritoneal carcinomatosis, it also provides the foundation for the development of a new translational research therapeutic programme at NCCS. In addition, the concept of targeting water beyond the traditional view of seed and soil potentially paves the way for a paradigm shift in how cancers can be treated.” said Asst Prof Ong, a Consultant in the Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology at Singapore General Hospital and National Cancer Centre Singapore, who treats patients with peritoneal carcinomatosis and is the Principal Investigator of the study.
The research team is currently working with multiple government agencies and pharmaceutical partners to harness the research findings of this study to realise the potential of targeting “water” in cancer patients.
This research is supported by the Singapore Ministry of Health (MOH)’s National Medical Research Council (NMRC) under its Transition Award (NMRC/TA/0061/2017) and the National Research Foundation Singapore under its Open Fund – Large Collaborative Grant (MOH-000206).
– END –
Publication’s citation: Hendrikson et al., Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis, Cell Reports Medicine (2022),
For media queries and clarifications, please contact:
National Cancer Centre Singapore
Assistant Manager, Corporate Communications
About National Cancer Centre Singapore (NCCS)
The National Cancer Centre Singapore (NCCS) is a leading national and regional tertiary cancer centre with specialists who are experts in treating cancer. NCCS attends to the majority of cancer cases in Singapore's public healthcare sector. In addition to offering holistic and multidisciplinary oncology care, our clinicians and scientists collaborate with local and international partners to conduct robust, cutting-edge clinical and translational research. To achieve the vision of being a global leading cancer centre, NCCS offers world-class care and shares its depth of experience and expertise by training local and overseas medical professionals.
To meet growing needs, the new NCCS building will be completed in 2022 with increased capacity and expanded facilities dedicated to cancer care, rehabilitation, research and education. To give patients the best treatment outcomes, NCCS will offer access to advanced and innovative treatment such as proton therapy at the new Goh Cheng Liang Proton Therapy Centre.
For more information, please visit:
1Couzin-Frankel J. Cancer Immunotherapy. Science. 2013 Dec 20; 342(6165):1432-3
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Crescent, Singapore 169610 +65 6436 8000